| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/22/2004 | WO2004032825A2 Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax |
| 04/22/2004 | WO2004032824A2 Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
| 04/22/2004 | WO2004032823A2 Treatment and rehydration composition which is used to limit the side effects of gastro-enteritis in adults |
| 04/22/2004 | WO2004032716A2 Compounds for modulation of cholesterol transport |
| 04/22/2004 | WO2004032709A2 Inhibition of src for treatment of reperfusion injury related to revascularization |
| 04/22/2004 | WO2004032708A2 Vasoregulating compounds and methods of their use |
| 04/22/2004 | WO2004032653A1 Methods and compositions for providing glutamine |
| 04/22/2004 | WO2004032629A1 Mixed compositions for controlling parasitic insects |
| 04/22/2004 | WO2004020430A3 Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics |
| 04/22/2004 | WO2004019959A9 Dna repair enzymes |
| 04/22/2004 | WO2004019758A3 Methods of treating idiopathic pulmonary fibrosis |
| 04/22/2004 | WO2004018431A3 Novel phenanthridines |
| 04/22/2004 | WO2004017979A3 Medicament, food supplement, and fodder additive |
| 04/22/2004 | WO2004017948A3 Use of lck inhibitor for treatment of immunologic diseases |
| 04/22/2004 | WO2004017941A3 Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist |
| 04/22/2004 | WO2004014852A3 Iminothiazolidinones as inhibitors of hcv replication |
| 04/22/2004 | WO2004014300A3 Tyrosine kinase inhibitors |
| 04/22/2004 | WO2004011031A9 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| 04/22/2004 | WO2004010945A3 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 04/22/2004 | WO2004009784A3 Novel inhibitors of kinases |
| 04/22/2004 | WO2004005544A3 Marker genes for determining renal toxicity |
| 04/22/2004 | WO2004005310A3 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 04/22/2004 | WO2004005243A3 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives |
| 04/22/2004 | WO2004003201A3 Antisense modulation of lrh1 expression |
| 04/22/2004 | WO2004002986A3 Novel benzimidazole derivatives |
| 04/22/2004 | WO2004000372A3 Disinfecting composition, cleaning tablet produced therefrom, and use thereof |
| 04/22/2004 | WO2004000313A3 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds |
| 04/22/2004 | WO2003105907A3 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases |
| 04/22/2004 | WO2003105906A8 A process for the preparation of piroxicam: b-cyclodextrin inclusion compounds |
| 04/22/2004 | WO2003103596A8 Stabilized nanoparticle formulations of camptotheca derivatives |
| 04/22/2004 | WO2003102012A3 New etonogestrel esters |
| 04/22/2004 | WO2003101958A3 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| 04/22/2004 | WO2003096965A3 Use of quinoline derivatives with anti-integrase effect and applications thereof |
| 04/22/2004 | WO2003093499A3 Therapeutic use of selective pde10 inhibitors |
| 04/22/2004 | WO2003092644A3 Mouth hygiene product containing sugar esters and sugar ethers as antimicrobial active ingredients |
| 04/22/2004 | WO2003088812A3 Nor-1 and nur77 nuclear receptors as targets for anti-leukemia therapy |
| 04/22/2004 | WO2003082263A8 Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases |
| 04/22/2004 | WO2003080810A3 αAED AND βAED REGULATION OF NUCLEAR TRANSCRIPTION, GENE REGULATION, AND/OR GENE EXPRESSION |
| 04/22/2004 | WO2003078403A3 Derives d’aminoindazoles comme inhibiteurs de proteine-kinase |
| 04/22/2004 | WO2003075943A3 Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol |
| 04/22/2004 | WO2003072106A3 Use of tyrosine kinase inhibitors for treating substance use disorders |
| 04/22/2004 | WO2003072015A3 Compounds useful in the treatment of anthrax |
| 04/22/2004 | WO2003070159A3 Novel coumarin and chromene compounds and methods of treating or preventing viral infections |
| 04/22/2004 | WO2003064625A3 Oligonucleotide compositions with enhanced efficiency |
| 04/22/2004 | WO2003063842A9 Composition for inhalation |
| 04/22/2004 | WO2003051300A8 Metal complexes and formulations of rifamycin analogues and uses therof |
| 04/22/2004 | WO2003051299A8 Sulfhydryl rifamycins and uses thereof |
| 04/22/2004 | WO2003041686A3 Improved therapy for topical diseases |
| 04/22/2004 | WO2003040345A3 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/22/2004 | WO2003029428A8 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 04/22/2004 | WO2003026563A9 Conjugated anti-psychotic drugs and uses thereof |
| 04/22/2004 | WO2003015809A9 Antimicrobial cationic peptides and formulations thereof |
| 04/22/2004 | WO2003005999A8 Methods of treating cytokine mediated diseases |
| 04/22/2004 | WO2002100390A3 Improved method of treating the syndrome of coronary heart disease risk factors in humans |
| 04/22/2004 | WO2002100148A3 Treatment or prophylaxis of insulin-producing cell graft rejection |
| 04/22/2004 | WO2002098857A8 New indole derivatives with 5-ht6 receptor affinity |
| 04/22/2004 | WO2002098362A3 Use of rank antagonists to treat cancer |
| 04/22/2004 | WO2002094794A8 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders |
| 04/22/2004 | WO2002092782A3 Diagnosis and treatment of malignant neoplasms |
| 04/22/2004 | WO2002090567A3 Sperm-specific cation channel, and uses therefor |
| 04/22/2004 | WO2002074767A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074752A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074748A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002064731A9 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 04/22/2004 | WO2002011711B1 Formulations of mometasone and a bronchodilator for pulmonary administration |
| 04/22/2004 | WO2001082949A9 Method of reducing side effects of chemotherapy in cancer patients |
| 04/22/2004 | WO2000061134A9 Antimicrobial agents |
| 04/22/2004 | US20040077902 Dicreatine maleate and method for making same |
| 04/22/2004 | US20040077896 Compounds for the treatment of metabolic disorders |
| 04/22/2004 | US20040077883 Suspending plant material or extract in the presence of an oxidizer, extracting terpene trilactones and separating |
| 04/22/2004 | US20040077879 Building blocks linked together through the formation of rigid diketopiperazine rings |
| 04/22/2004 | US20040077877 Jun n-terminal kinase inhibitors |
| 04/22/2004 | US20040077875 (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer |
| 04/22/2004 | US20040077871 Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists |
| 04/22/2004 | US20040077859 Immunosuppressive effects of pteridine derivatives |
| 04/22/2004 | US20040077858 Making 4-(1H-indol-5-yloxy)-pyrrolo(2,1-f)(1,2,4)triazine compounds that are tyrosine kinase inhibitors; reducing vascular permeability; anticancer agents |
| 04/22/2004 | US20040077856 Peptide deformylase inhibitors |
| 04/22/2004 | US20040077855 Thrombopoietin mimetics |
| 04/22/2004 | US20040077854 4-chloro-N-((5-((4-(hexylamino)piperidin-1-yl)sulfonyl)thien-2 -yl)methyl)benzamide for example; JUN kinase inhibitors to treat nervous system disorders, cancer, cardiovascular and autoimmune disorders |
| 04/22/2004 | US20040077851 Receptor selective cannabimimetic aminoalkylindoles |
| 04/22/2004 | US20040077850 For treating human/animal gram-positive/negative bacteria infections |
| 04/22/2004 | US20040077848 Reacting a polysaccharide from fermentation with isopropanol in a highly saline aqueous solution, n-deacetylation followed by n-sulfation, and treating ammonium salt with an o-sulfating agent |
| 04/22/2004 | US20040077847 Nucleic acid encoding a pneumoccocal surface protein c gene or epitope |
| 04/22/2004 | US20040077780 Thermogelling oligopeptide polymers |
| 04/22/2004 | US20040077731 Method and compound for antagonizing inhibition effects of alcohol on cell adhesion |
| 04/22/2004 | US20040077730 Carbocyclic halo amines such as N,N-dimethyl-1-(1-(4-chloro-phenyl)cyclobutyl)-3-methylbutyl amine hydrochloride, used for reducing insulin resistance in humans having diabetes |
| 04/22/2004 | US20040077728 Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage |
| 04/22/2004 | US20040077727 Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23 |
| 04/22/2004 | US20040077726 Antiproliferative and anticarcinogenic agents; psoriasis |
| 04/22/2004 | US20040077725 Solid dosage form of nateglinide for oral administration |
| 04/22/2004 | US20040077724 Compositions comprising an o/w emulsion containing conjugated linoleic acid |
| 04/22/2004 | US20040077723 Administering mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) to treat cardiovascular disorders |
| 04/22/2004 | US20040077722 Cosmetics for dermatological treatment and prevention of skin aging due to actinic radiation |
| 04/22/2004 | US20040077720 Inhibition of antibody production employing perfluorooctanoic acid or derivatives thereof |
| 04/22/2004 | US20040077719 Food supplements, feed additives, dietetic, cosmetics |
| 04/22/2004 | US20040077718 Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis |
| 04/22/2004 | US20040077717 Method of treating neutrophil-related diseases with topical anesthetics |
| 04/22/2004 | US20040077715 Use of an isothiocyanate, a thiocyanate or a mixture thereof as depigmenting agent |
| 04/22/2004 | US20040077710 Methods of treatment during vascular procedures |
| 04/22/2004 | US20040077709 Neuronal death inhibitors |